Deep learning-based multi-drug synergy prediction model for individually tailored anti-cancer therapies.

She, Shengnan; Chen, Hengwei; Ji, Wei; Sun, Mengqiu; Cheng, Jiaxi; Rui, Mengjie; Feng, Chunlai

She, Shengnan; Chen, Hengwei; Ji, Wei; Sun, Mengqiu; Cheng, Jiaxi; Rui, Mengjie; Feng, Chunlai.

Afiliação

She S; Department of Pharmaceutics, School of Pharmacy, Jiangsu University, Zhenjiang, China.
Chen H; Department of Pharmaceutics, School of Pharmacy, Jiangsu University, Zhenjiang, China.
Ji W; Department of Pharmaceutics, School of Pharmacy, Jiangsu University, Zhenjiang, China.
Sun M; Department of Pharmaceutics, School of Pharmacy, Jiangsu University, Zhenjiang, China.
Cheng J; Department of Pharmaceutics, School of Pharmacy, Jiangsu University, Zhenjiang, China.
Rui M; Department of Pharmaceutics, School of Pharmacy, Jiangsu University, Zhenjiang, China.
Feng C; Department of Pharmaceutics, School of Pharmacy, Jiangsu University, Zhenjiang, China.

Front Pharmacol ; 13: 1032875, 2022.

Article em En | MEDLINE | ID: mdl-36588694

Palavras-chave

anti-cancer combination therapy; cancer cell subtype-specific models; deep learning framework; high-order drug combinations; precision oncology

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Front Pharmacol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google